Exploratory study of long-term health-related quality of life in patients with surgically treated primary parotid gland cancer

Head and Neck

Volumn 38, Issue 1, 2016, Pages 111-117

  Stenner, Markus ^a   Beenen, Franziska ^b   Hahn, Moritz ^b   Koopmann, Mario ^a   Weiss, Daniel ^a   Hüttenbrink, Karl Bernd ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

facial nerve palsy; parotid gland cancer; prognosis; quality of life; risk factors

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CROSS-SECTIONAL STUDY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30 HEAD AND NECK 35; EXPLORATORY RESEARCH; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; PAROTID GLAND CANCER; POSTOPERATIVE CARE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEX DIFFERENCE; CANCER STAGING; FOLLOW UP; MIDDLE AGED; PAROTID NEOPLASMS; PROCEDURES; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM STAGING; PAROTID NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84955625033     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23858     Document Type: Article

References (32)

1. Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Tumours of the salivary gland. Pathology and genetics. Head and neck tumours. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2005. pp 209-281.
2. Vander Poorten VL., Salivary gland carcinoma-stepping up the prognostic ladder. Amsterdam, The Netherlands: University of Amsterdam, 2002.
3. Boukheris H, Curtis RE, Land CE, Dores GM,. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18: 2899-2906.
4. Chandana SR, Conley BA,. Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev Anticancer Ther 2008; 8: 645-652.
5. Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE,. Salivary gland carcinomas. Oral Maxillofac Surg 2012; 16: 267-283.
6. Nagliati M, Bolner A, Vanoni V, et al., Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori 2009; 95: 442-448.
7. Poorten VV, Hart A, Vauterin T, et al., Prognostic index for patients with parotid carcinoma: international external validation in a Belgian-German database. Cancer 2009; 115: 540-550.
8. Trask PC, Hsu MA, McQuellon R,. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J 2009; 15: 435-440.
9. Reeve BB, Wyrwich KW, Wu AW, et al., ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 2013; 22: 1889-1905.
10. Aaronson NK, Ahmedzai S, Bergman B, et al., The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
11. Cocks K, King MT, Velikova G, Fayers PM, Brown JM,. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 2008; 44: 1793-1798.
12. Singer S, Arraras JI, Chie WC, et al., Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients EORTC QLQ-H&N35: a methodological review. Qual Life Res 2013; 22: 1927-1941.
13. Ho AL, Scott AM, Klassen AF, Cano SJ, Pusic AL, Van Laeken N,. Measuring quality of life and patient satisfaction in facial paralysis patients: a systematic review of patient-reported outcome measures. Plast Reconstr Surg 2012; 130: 91-99.
14. Ciuman RR, Oels W, Jaussi R, Dost P,. Outcome, general, and symptom-specific quality of life after various types of parotid resection. Laryngoscope 2012; 122: 1254-1261.
15. Beutner D, Wittekindt C, Dinh S, Huttenbrink KB, Guntinas-Lichius O,. Impact of lateral parotidectomy for benign tumors on quality of life. Acta Otolaryngol 2006; 126: 1091-1095.
16. Erkan AN, Yavuz H, Ozer C, Ozer F, Ozluoglu L,. Quality of life after surgery for benign disease of the parotid gland. J Laryngol Otol 2008; 122: 397-402.
17. Nitzan D, Kronenberg J, Horowitz Z, et al., Quality of life following parotidectomy for malignant and benign disease. Plast Reconstr Surg 2004; 114: 1060-1067.
18. Al-Mamgani A, van R ooij, P, Verduijn, GM, Meeuwis, CA, Levendag, PC,. Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den Hoed Cancer Center. Int J Radiat Oncol Biol Phys 2012; 84: 189-195.
19. Scott NW, Fayers PM, Aaronson NK, et al., EORTC QLQ Reference Values. Brussels, Belgium: Quality of Life Department, EORTC Headquarters; 2008.
20. Osoba D, Rodrigues G, Myles J, Zee B, Pater J,. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
21. Luukkaa H, Klemi P, Leivo I, et al., Salivary gland cancer in Finland 1991-96: an evaluation of 237 cases. Acta Otolaryngol 2005; 125: 207-214.
22. Stenner M, Molls C, Klussmann JP, Hüttenbrink KB,. Prognosis of surgically treated primary parotid gland cancer-an evaluation of 231 cases. Laryngorhinootologie 2011; 90: 664-671.
23. Kreppel M, Scheer M, Meyer M, et al., Comparison of TNM-based stage grouping versus UICC/AJCC stage grouping (7th edition) in malignant parotid gland tumors. Oral Oncol 2013; 49: 903-910.
24. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S,. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). J Clin Oncol 1998; 16: 1188-1196.
25. Schwarz R, Hinz A,. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001; 37: 1345-1351.
26. George M, Karkos PD, Dwivedi RC, Leong SC, Kim D, Repanos C,. Preservation of greater auricular nerve during parotidectomy: sensation, quality of life, and morbidity issues. A systematic review. Head Neck 2014; 36: 603-608.
27. Dijkema T, Raaijmakers CP, Ten Haken RK, et al., Parotid gland function after radiotherapy: the combined Michigan and Utrecht experience. Int J Radiat Oncol Biol Phys 2010; 78: 449-453.
28. Coulson SE, O'dwyer NJ, Adams RD, Croxson GR,. Expression of emotion and quality of life after facial nerve paralysis. Otol Neurotol 2004; 25: 1014-1019.
29. Dobel C, Miltner WH, Witte OW, Volk GF, Guntinas-Lichius O,. Emotional impact of facial palsy [in German]. Laryngorhinootologie 2013; 92: 9-23.
30. Stodulski D, Mikaszewski B, Stankiewicz C,. Signs and symptoms of parotid gland carcinoma and their prognostic value. Int J Oral Maxillofac Surg 2012; 41: 801-806.
31. Singer S, Arraras JI, Baumann I, et al., Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy-update of the EORTC QLQ-H&N35, phase I. Head Neck 2013; 35: 1331-1338.
32. Gliklich RE, Goldsmith TA, Funk GF. Are head and neck specific quality of life measures necessary? Head Neck 1997;19: 474-480.